Stocks Health care QCLS
NASDAQ · Health careQ/C Technologies, Inc. (QCLS)
It posted a net loss of $16.6M. In fiscal 2025 capital spending exceeded operating cash flow by $10.8M. At June 30, 2026 it held $307.6K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Q/C Technologies, Inc. does
Q/C Technologies, Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker QCLS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$11.6M | -$8.66 | -$10.8M |
| 2024 | n/a | -$23.4M | -$1,080.87 | n/a |
| 2023 | n/a | -$4M | -$516.68 | n/a |
| 2022 | n/a | -$15.2M | -$1,138.06 | n/a |
| 2021 | n/a | -$29.9M | -$2,480.40 | n/a |
| 2020 | n/a | -$9.5M | -$7,266.10 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Q/C Technologies, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- September 11, 2026
- August 12, 2026
- July 2, 2026
- May 15, 2026
- April 29, 2026
- April 15, 2026
- March 31, 2026Late annual report notice NT 10-K
- March 13, 2026Auditor change 8-K
- February 11, 2026
Insider trades
What the people running Q/C Technologies, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 30, 2026 | Voss Chelsea SierraDirector | Boughtindirect | 1,753 | $5.5K |
Who owns QCLS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| PharmaCyte Biotech, Inc.13D, may seek influence | 74% | November 18, 2025 |
Largest institutional holders
Insiders
1 insiders reported holding 61,555 shares in total, about $53.4K at the last price.
| Holder | Shares |
|---|---|
| Voss Chelsea SierraDirector | 61,55561,555 held indirectly |
Questions about QCLS
What does Q/C Technologies, Inc. do?
Q/C Technologies, Inc. is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker QCLS.
Is Q/C Technologies, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $16.6M.
When did Q/C Technologies, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new insider holdings from September 22, 2026.
Similar companies
Compare QCLS with
Follow QCLS
Get an email when Q/C Technologies, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow QCLS: get an email when it filesWhere the numbers come from
Financial figures are the values Q/C Technologies, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.